Trial Profile
A Phase II, Randomized Study to Assess the Pharmacokinetics, Safety and Pharmacodynamics of Single and Repeat Doses of RPL554 Administered by Dry Powdered Inhaler in Patients With COPD
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 May 2021
Price :
$35
*
At a glance
- Drugs Ensifentrine (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Pharmacokinetics; Therapeutic Use
- Sponsors Verona Pharma
- 20 May 2020 Results presented at the 116th International Conference of the American Thoracic Society
- 01 May 2020 Results published in the Verona Pharma Media Release.
- 01 May 2020 According to a Verona Pharma media release, data from this study is published as an abstract on the ATS website and today in the peer reviewed publication, American Journal of Respiratory and Critical Care Medicine.